论文部分内容阅读
目的观察替格瑞洛联合替罗非班用于急性ST段抬高型心肌梗死患者行经皮冠状动脉介入治疗的有效性及安全性。方法选取笔者进修医院所收治的急性ST段抬高型心肌梗死(STEMI)患者120例为研究对象,随机分为观察组和对照组,每组60例。对照组采用替罗非班与阿司匹林联合治疗,观察组在对照组治疗基础上联合替格瑞洛进行治疗。观察2组不同时间段的血小板聚集率及患者手术过程中不良事件发生情况。结果服药后,观察组各个时间点血小板聚集率均低于对照组(P<0.05)。2组出血率比较差异无统计学意义(P>0.05);观察组心血管事件发生率为1.7%,低于对照组的11.7%(P<0.05)。结论 STEMI患者在进行经皮冠状动脉介入治疗的过程中采用替格瑞洛联合替罗非班的治疗方法,具有良好的治疗效果及安全性,值得临床推广应用。
Objective To observe the efficacy and safety of ticagrelor combined with tirofiban for percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Methods A total of 120 acute ST-elevation myocardial infarction (STEMI) patients admitted to our hospital were selected as study subjects and randomly divided into observation group and control group, 60 cases in each group. The control group was treated with tirofiban and aspirin. The observation group was treated with ticagrelor on the basis of the control group. The platelet aggregation rate and the incidence of adverse events during the operation of the two groups were observed. Results After taking the drug, the platelet aggregation rate of the observation group at each time point was lower than that of the control group (P <0.05). There was no significant difference in bleeding rate between the two groups (P> 0.05). The incidence of cardiovascular events in the observation group was 1.7%, which was lower than that of the control group (11.7%, P <0.05). Conclusion STEMI patients treated with ticagrelor combined with tirofiban in the course of percutaneous coronary intervention have good therapeutic effect and safety, which is worthy of clinical application.